

## ASX Release

### Anatara receives \$888,049 R&D Tax Refund

MELBOURNE, 03 February 2021: Anatara Lifesciences (ASX: ANR) is pleased to announce that it has received \$888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme. Anatara, as of today, has \$4.38 million in cash plus term deposits including \$2.38 million in cash and \$2 million in a term deposit.

This refund is from Anatara's 2019-2020 research activities and reflects a period of significant investment in the Company's Gastrointestinal ReProgramming (GaRP) complementary medicine which aims to: (1) address dysbiosis of the microbiome; (2) reduce gut inflammation; and (3) promote mucosal healing.

Anatara's CEO, Mr. Steven Lydeamore said, "The R&D tax incentive scheme provides an important source of funding through prudent management and enables the Company to progress the development and commercialisation of our GaRP product."

Anatara will continue to execute its human health development plans and commercialisation of both GaRP and Detach®. Looking ahead, key company milestones anticipated:

Milestone	Date
GaRP human clinical study in IBS	Commencement: early 2021
BONIFF-SMEC piglet challenge study for enterotoxigenic <i>Escheria coli</i>	Completion: mid 2021
GaRP licence/commercialisation deal(s)	Completion: H1, 2021

#### For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

## About Anataara Lifesciences Ltd

Anataara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataara is a life sciences company with expertise in developing products for animal and human health. Anataara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

## Anataara's Gastrointestinal ReProgramming (GaRP) dietary supplement

Anataara's GaRP complementary medicine is being developed to specifically target two human gastrointestinal disorders, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). IBS is the most common GI condition affecting approximately 11% of the global population<sup>2</sup> while IBD affects an estimated five million people globally.<sup>3</sup>

Current pharmaceutical treatments have high failure rates and severe side-effects, leading to over 50% of IBS<sup>4</sup> and IBD<sup>5</sup> patients trying complementary and alternative medicines (CAMs) in the hope of effectively managing their chronic bowel condition. As many patients and healthcare providers believe the risk benefit of CAMs to be favourable, patients are willing to invest in their health, with this market segment being significant. In 2018, expenditure on gastrointestinal supplements and OTC digestive remedies in the US alone was US\$8 billion.<sup>6,7</sup>

<sup>1</sup> Sperber et. al. Gastroenterology 2020; 1–16 .

<sup>2</sup> Clinical Gastroenterology and Hepatology 2012; 10, 712-721.

<sup>3</sup> Crohn's and Colitis Australia.

<sup>4</sup> Grundmann O & Yoon S (2014) World J. Gastroenterol 20 (2). p.346.

<sup>5</sup> Lovell R & Ford A (2012) Clin. Gastroenterol. Hepatol. 10. p.712

<sup>6</sup> Mintel's 2018 Digestive Health U.S., July 2019.

<sup>7</sup> 2018 category insight Report: follow your gut-a global look at Digestive Health Products.

### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anataara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email [info@anataara.com](mailto:info@anataara.com) | Website [anataaralifesciences.com](http://anataaralifesciences.com)

